Edwards Lifesciences Corporation
A maker of replacement heart valves, from the SAPIEN transcatheter valves threaded to the heart through a thin tube instead of open surgery to surgical valves like INSPIRIS RESILIA. It began in 1958 when Miles "Lowell" Edwards, a retired hydraulic engineer who once built fuel pumps, teamed with surgeon Albert Starr to build an artificial heart — a goal that instead yielded the first Starr-Edwards ball-and-cage valve. It later spun off from Baxter in 2000.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
fell 27.4% in Q2 2026 even as grew. Revenue rose 13.6% to $1,741.0M and dropped 25.0% to $0.42 as TMTT sales rose 47.7% and TAVR rose 11.3%, while a higher cut profit. The business is growing but tax and one-off items are weighing on earnings.
Q2 FY2026 sales rose 13.6% to $1.74B, led by TMTT (+47.7%) and TAVR (+11.3%), while tax items drove a higher effective rate.
Interest Rate Risk, Foreign Currency Risk, Credit Risk, and Concentrations of Risk For a complete discussion of our exposure to interest rate risk, foreign currency risk, credit risk, and concentrations of risk, refer to Item 7A Quantitative and Qualitative Disclosures About Mar…
Interest Rate Risk, Foreign Currency Risk, Credit Risk, and Concentrations of Risk For a complete discussion of our exposure to interest rate risk, foreign currency risk, credit risk, and concentrations of risk, refer to Item 7A Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes from the information discussed therein. Investment Risk We are exposed to investment risks related to changes in the underlying financial condition and credit capacity of certain of our investments. As of June 30, 2026, we had $1,389.0 million of investments in debt securities, of which $42.8 million were long-term. In addition, we had $201.3 million of investments in equity instruments of public and private companies. Should these companies experience a decline in financial performance, financial condition or credit capacity, or fail to meet certain development milestones, a decline in the investments' value may occur, resulting in unrealized or realized losses. See Note 5 to the Condensed Consolidated Financial Statements for additional information.
Read original filing text →Please see Part I, Item 1, Note 12 to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q for a description of our legal proceedings, which is incorporated by reference herein.
Please see Part I, Item 1, Note 12 to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q for a description of our legal proceedings, which is incorporated by reference herein.
Read original filing text →A description of the risk factors associated with our business is contained in the “Risk Factors” section of our Annual Report on Form 10-K for our fiscal year ended December 31, 2025. There have been no material changes to our Risk Factors as previously reported.
A description of the risk factors associated with our business is contained in the “Risk Factors” section of our Annual Report on Form 10-K for our fiscal year ended December 31, 2025. There have been no material changes to our Risk Factors as previously reported.
Read original filing text →